Estramustine phosphate sodium

Estramustine phosphate sodium is an antimicrotubule chemotherapy agent; arrests prostate cancer cells in the G2/M phase of the cell cycle. (In Vitro) :Estramustine phosphate sodium (1 μg/ mL, 48 h) suppresses PC3 cell growth.Estramustine phosphate sodium (2 μg/mL, 48 h) elevates phosphatidylserine eversion amount on PC3 cells and induces PC3 cell apoptosis through reducing miR-31.Estramustine phosphate sodium (0-40 μM, 24-72 h) inhibits cell proliferation and tubulin cytoskeleton in RAW 264.7 cells.Estramustine phosphate sodium (10 μM, 24 h) inhibits TGF-β-induced RAW 264.7 cell migration, as well as TGF-β-induced uPA production by inhibiting Smad3 activation. (In Vivo) :Estramustine phosphate sodium (Intraperitoneal injection, 4 or 12 mg/kg, a daily dose for 2 weeks) inhibits PAC120 tumor growth 53% by day 35.